Search

everythinglearnresearchcommunity

for

Search:↓

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

The Rotterdam Study updated findings on elderly health, focusing on heart disease, genetics, lifestyle effects, and disease understanding.

The Rotterdam Study updated its design and objectives in 2012, providing insights into various diseases in the elderly, including skin cancer, bone health, liver disease, neurological and psychiatric conditions, and respiratory issues.

The Rotterdam Study aims to understand various diseases in older adults.

The article concludes that better understanding gene regulation related to seasonal changes can offer insights into the mechanisms of seasonal timing in mammals.

The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.

AMH helps estimate ovarian reserve but doesn't predict pregnancy chances; age is more important.

Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Lipocalin-2 levels are higher in women with PCOS and may indicate insulin resistance.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Spironolactone harms fish reproduction and is more potent in fish than invertebrates, needing environmental monitoring.

Researchers found that most genes affecting drug responses are not fully covered by commercial SNP chips, suggesting the need for more comprehensive tools to optimize drug selection based on genetics.

Finasteride exposure affects gene expression and anogenital distance in male rat fetuses.

Stem cell therapies show promise for treating various diseases but face challenges in clinical use and require better monitoring techniques.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

The document explains the difficulty in diagnosing and treating brain diseases caused by the immune system and stresses the need for quick and accurate tests.

The index to ring finger ratio may indicate disease severity in female ankylosing spondylitis patients, but not in males.

Organic selenium may offer better retention and less waste in puppies.

MRI helps distinguish between pituitary adenomas and craniopharyngiomas, guides treatment for pediatric CNS tumors, and assesses rhinocerebral mucormycosis with a high mortality rate in transplanted patients.

The Rotterdam Study investigates diseases in older adults and has produced many research findings.

The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.

The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.

Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.

The guidelines suggest lifestyle changes, diet adjustments, and personalized medication to manage dyslipidemia and reduce heart disease risk.

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

The Rotterdam Study aims to understand disease causes in the elderly and has found new risk factors and genetic influences on various conditions.

Growing human skin cells in a 3D environment can stimulate new hair growth.

The document concludes that the fast-growing direct-to-consumer genetic testing market lacks sufficient regulation, posing risks to consumers due to questionable test quality and accuracy.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.